Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate Chemical Properties

Melting point:

168 °C

storage temp. 

2-8°C

solubility 

Chloroform (Slightly), Methanol (Slightly, Sonicated)

form 

Solid

color 

Off-White to Light Yellow

InChI

InChI=1S/C25H21N3O3/c1-3-31-25-27-22-10-6-9-21(24(29)30-2)23(22)28(25)16-17-11-13-18(14-12-17)20-8-5-4-7-19(20)15-26/h4-14H,3,16H2,1-2H3

InChIKey

KSXLHOFDCDKQLH-UHFFFAOYSA-N

SMILES

C1(OCC)N(CC2=CC=C(C3=CC=CC=C3C#N)C=C2)C2=C(C(OC)=O)C=CC=C2N=1

Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate Usage And Synthesis

Description

Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate is a key synthetic intermediate in the synthesis of azilsartan, an angiotensin II.1 (AT1) receptor antagonist used in the treatment of hypertension.

Chemical Properties

Pale Yellow Solid

Uses

Intermediate in the synthesis of angiotensin II receptor antagonist.

Synthesis

Using methyl 3-amino-2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)benzoate (MBA) and tetraethyl orthocarbonate (TEC, 397 kg) as the raw material, the mixture was heated at reflux in the presence of acetic acid (62 kg) at 78 to 82 °C for 1 to 2 hours. After completion of the reaction, the reaction solution was cooled and methanol (1680 L), 24% aqueous sodium hydroxide (65 L) and water (2030 L) were added sequentially. The mixture was stirred at 60 to 30 °C for 2 h and the pH was adjusted with aqueous sodium hydroxide solution to 5 to 7. After cooling to below 5 °C, the precipitated crystals were separated and washed with cold water (2500 L) and cold ethyl acetate (500 L) to obtain the first batch of crystals. The mother liquor and washings were concentrated under reduced pressure, cooled to below 5 °C, and the precipitated crystals were separated and washed with cold ethyl acetate (20 L) to obtain the second batch of crystals. The first and second batches of crystals were combined, dissolved in ethyl acetate (4890 L) and heated to reflux. The crystal seeds were added at about 70 °C and then cooled to 5 °C. The crystals were separated, washed with cold ethyl acetate (200 L) and dried to give methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate (BEC, 361 kg, 84.8% yield). The product melting point was 168.5-169.5 °C. 1H-NMR (200 MHz, CDCl3) δ: 1.42 (3H, t), 3.71 (3H, s), 4.63 (2H, q), 5.59 (2H, s), 7.09 (2H, d), 7.20 (1H, t), 7.45-7.59 (5H, m), 7.69- 7.80 (2H, m), 7.92 (1H, dd).IR (KBr) cm-1: 2225, 1725, 1550, 1480, 1430, 1280, 1250, 1040, 760, 750.

References

[1] Journal of Medicinal Chemistry, 1993, vol. 36, # 15, p. 2182 - 2195
[2] Patent: EP1420016, 2004, A1. Location in patent: Page 18-19
[3] Patent: WO2009/157001, 2009, A2. Location in patent: Page/Page column 3

Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate(139481-44-0)Related Product Information

• Tribenuron methyl
• Methyl 4-cyanobenzoate
• Kresoxim-methyl
• Methyl carbamate
• Benzimidazole
• Methyl salicylate
• Methyl benzoate
• Methylparaben
• Ethyl-2-Ethoxy-1-[[(2'-Cyanobiphenyl-4-yl) Methyl] Benzimidazole]-7-Carboxylate
• Methyl anthranilate
• Methyl formate
• METSULFURON METHYL
• Candesartan
• Candesartan cilexetil
• Trityl candesartan
• Ethyl -2-ethoxy-1-[[(2-(1Htetrazol-5-yl)biphenyl-4-yl-) methyl]
• Thiophanate-methyl
• Methyl